ProKidney Corp. (NASDAQ:PROK - Get Free Report) shares traded down 6.9% during mid-day trading on Friday . The company traded as low as $2.75 and last traded at $2.78. 1,938,753 shares changed hands during trading, a decline of 64% from the average session volume of 5,384,855 shares. The stock had previously closed at $2.98.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. Zacks Research lowered shares of ProKidney from a "strong-buy" rating to a "hold" rating in a report on Monday, August 18th. Guggenheim reaffirmed a "buy" rating and set a $7.00 price objective (up from $6.00) on shares of ProKidney in a report on Monday, July 14th. UBS Group increased their price objective on shares of ProKidney from $4.00 to $8.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Citigroup reaffirmed a "buy" rating and set a $9.00 price objective (up from $6.00) on shares of ProKidney in a report on Wednesday, July 9th. Finally, Wall Street Zen raised shares of ProKidney from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $6.25.
Read Our Latest Report on PROK
ProKidney Price Performance
The firm has a market capitalization of $771.01 million, a P/E ratio of -4.60 and a beta of 1.74. The firm has a 50-day moving average price of $2.83 and a two-hundred day moving average price of $1.52.
ProKidney (NASDAQ:PROK - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. The business had revenue of $0.22 million for the quarter. Sell-side analysts predict that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.
Insider Transactions at ProKidney
In other news, insider Darin J. Weber sold 103,480 shares of the business's stock in a transaction dated Tuesday, July 8th. The stock was sold at an average price of $3.02, for a total transaction of $312,509.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 41.49% of the stock is owned by company insiders.
Institutional Investors Weigh In On ProKidney
A number of large investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd acquired a new position in ProKidney in the second quarter valued at approximately $36,000. AQR Capital Management LLC lifted its holdings in ProKidney by 106.4% in the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock valued at $46,000 after acquiring an additional 27,098 shares during the period. ProShare Advisors LLC lifted its holdings in ProKidney by 57.3% in the fourth quarter. ProShare Advisors LLC now owns 30,879 shares of the company's stock valued at $52,000 after acquiring an additional 11,250 shares during the period. Deutsche Bank AG raised its stake in shares of ProKidney by 49.4% during the 1st quarter. Deutsche Bank AG now owns 86,337 shares of the company's stock worth $76,000 after buying an additional 28,546 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in shares of ProKidney during the 4th quarter worth approximately $110,000. Hedge funds and other institutional investors own 51.59% of the company's stock.
About ProKidney
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Further Reading
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
